Lupus in Medical Technology

First Potential Lupus-Specific Treatment in Sight

... lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had ... The study is the largest ever to be completed for lupus and the first Phase III (late stage) trial of a new biologic immune therapy for lupus to succeed in meeting its primary endpoint and ...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

... First Phase 3 lupus Drug Trial in Decades to Show Effectiveness ... NEW YORK, July 20 /PRNewswire-USNewswire/ -- The lupus Research Institute (LRI) and its National ... on our way to the first new treatment for lupus in 50 years," said LRI President, Margaret G. ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled ... called BLyS-specific inhibitors. No new drug for lupus has been approved by regulatory authorities in ... first medicine being developed specifically for lupus that has reached this late stage of clinical ...

Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students

... -- To foster and support the next generation of lupus researchers, the lupus Foundation of America (LFA), Inc. has awarded ... studies under the supervision of an established lupus investigator. Named after the daughter of former ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all ... two Phase 3 trials of LymphoStat-B in systemic lupus erythematosus (SLE) in July and November, ... (belimumab) in patients with active systemic lupus erythematosus (SLE). The Company expects to ...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

... patients with active moderate and severe systemic lupus erythematosus (SLE). These findings ... here today. "Given the debilitating effect lupus has on a patient's quality of life, these results ... President and Chief Executive Officer of the lupus Foundation of America. "It has been nearly five ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

... (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed ... score (which would indicate a severe flare of lupus disease activity) and no more than one new BILAG ... first line of defense against infection. In lupus and certain other autoimmune diseases, ...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

... MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully ... the effects of MEDI-545 on disease activity in lupus patients. This randomized, double-blind, ... activity with single doses in patients with lupus and demonstrated an acceptable safety profile," ...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

... in patients with serologically active systemic lupus erythematosus (SLE). The results are the subject ... first line of defense against infection. In lupus and certain other autoimmune diseases, elevated ... . For more information on lupus, visit the lupus Foundation of America at http://www.lupus.org ...

Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues

... legislative priority is increased support for lupus research by Federal agencies such as the National ... and continued Federal research funding for lupus and other women's health issues," says ALR President Barbara Boyts. lupus causes unpredictable symptoms ranging from ...

Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus

... from Sandra C. Raymond, President & CEO of the lupus Foundation of America: "Demonstrating the impact of a treatment in a lupus clinical trial can be difficult, as lupus manifests itself differently in different ...

Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies

... drug candidate may help patients with Systemic lupus Erythematosus ... product candidate, R788, has successfully treated lupus prone mice and significantly improved their ... expects to initiate a Phase 2 clinical trial in lupus in the second half of 2008. The study, which ...

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials

... (belimumab) in patients with active systemic lupus erythematosus (SLE). LymphoStat-B is being ... score (which would indicate a severe flare of lupus disease activity) and no more than one new BILAG ... first line of defense against infections. In lupus and certain other autoimmune diseases, elevated ...

Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus

... identified multiple genes linked to systemic lupus erythematosus (SLE), or lupus, a debilitating ... affects an estimated 1.4 million Americans. lupus can affect the joints, kidneys, heart, lungs, ... difficult to diagnose. In 2005 the Alliance for lupus Research (ALR) formed and supported ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... standard of care in patients with active systemic lupus erythematosus (SLE). The results will be the ... under the agreement. About Systemic lupus Erythematosus Systemic lupus erythematosus (SLE) is a chronic, ...

Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus

... drug candidate for the treatment of Systemic lupus Erythematosus, or SLE. The candidate, CPG 52364, ... 2007 from 8:00am to 4:30pm EST. About Systemic lupus Erythematosus (SLE)(1) SLE is a chronic ... of CPG 52364 for the treatment of Systemic lupus Erythematosus (SLE); confirmation of TLR7/8/9 as ...

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure

... but are more likely in patients with such a history. Systemic lupus Erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus. Lithium Interaction Lithium generally should not ...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

... asthma, but are more likely in patients with such a history. Systemic lupus Erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus. Lithium Interaction Lithium generally should not be ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... - Albuferon(R) for hepatitis C and LymphoStat-B(R) for lupus on track for potential launch in 2010 - - ... BLyS(TM) (B-lymphocyte stimulator), for the treatment of systemic lupus erythematosus SLE In November 2007, Phase 2 results were presented at ...

New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)

... asthma, but are more likely in patients with such a history. Systemic lupus Erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus. Lithium Interaction Lithium generally should not be ...

New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments

... "This work required the collection and genotyping of thousands of RA and lupus patients and volunteers, a task that would have been difficult ... tissue growth & repair at Genentech, Inc. was a key collaborator on the lupus research. The NARAC team is also part of the whole genome association ...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

... a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... November 2009 BLISS-52 and BLISS-76, the ongoing Phase 3 trials of LymphoStat-B (belimumab), are the largest clinical trials ever conducted in lupus patients. HGS expects to report the first Phase 3 data for LymphoStat-B in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

... a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: Anne ...

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients

... a history of reduced urine output, or have allergic reactions to certain drugs known as sulfonamides and tell your doctor if you have liver problems, lupus or if you take lithium. Your doctor or pharmacist can give you a complete list of the ingredients in LOTREL or the benazepril and HCTZ combination. ...

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials

... a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . Contact: Anne Bowdidge ...

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus

... completion of a Phase Ib clinical study of TRX1, a novel humanized anti-CD4 monoclonal antibody (MAb), in subjects with refractory cutaneous lupus erythematosus (CLE). The Phase Ib study was designed to assess the safety, tolerability, and pharmacokinetics of TRX1. Tolerx has received a ...

Schering-Plough Reports Top-Line Results of the IDEAL Study

... hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), ...

Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma

... follicular NHL will be evaluated for efficacy. Trubion's TRU-015 is also being developed for the treatment of rheumatoid arthritis and systemic lupus erythematosus. About TRU-015 and SMIP Therapeutics Trubion and Wyeth Pharmaceuticals are developing SMIP therapeutics directed to CD20, an ...

Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood

... are more likely in patients with such a history -- Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus -- Lithium generally should not be given with thiazides -- Thiazides should be used with caution in patients with severe renal ...